RecruitingPhase 3NCT07235319
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Intervention
- Immediate locoregional radiotherapy(radiation)
- Enrollment
- 260 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2034
Study locations (5)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Hunan Cancer Hospital, Changsha, China
- Fujian Cancer Hospital, Fuzhou, China
- Zhejiang Cancer Hospital, Hangzhou, China
- Guangxi Medical University Cancer Hospital, Nanning, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07235319 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07584499Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsSun Yat-sen University
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGPHASE3NCT07459296Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCFirst Affiliated Hospital of Guangxi Medical University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu